LAUNXP Biomedical , Ltd Long Term Debt

As of the most recent data (June 2026), 6876.TWO shows a long-term debt of $3.2M. That compares with $12M in the prior-year period — down 74.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6876.TWO's long-term debt is now $3.2M (was $12M) — a 74.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether LAUNXP Biomedical , Ltd is outperforming or lagging.

Tracking 6876.TWO's long-term debt over time shows whether LAUNXP Biomedical , Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $3.2M That compares with $12M in the prior-year period — down 74.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has LAUNXP Biomedical , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $3.2M) with ownership activity and broader fundamentals.

LAUNXP Biomedical , Ltd's long-term debt is $3.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.